Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Review
. 2019 Nov;34(11):1629-1642.
doi: 10.1002/mds.27894. Epub 2019 Nov 6.

Multiple System Atrophy: Recent Developments and Future Perspectives

Wassilios G Meissner  1   2   3   4 , Pierre-Olivier Fernagut  2   3   5   6 , Benjamin Dehay  2   3 , Patrice Péran  7 , Anne Pavy-Le Traon  8 , Alexandra Foubert-Samier  1   2   9 , Miguel Lopez Cuina  2   3 , Erwan Bezard  2   3 , François Tison  1   2   3 , Olivier Rascol  10
Affiliations
Review

Multiple System Atrophy: Recent Developments and Future Perspectives

Wassilios G Meissner et al. Mov Disord. 2019 Nov.

Abstract

Multiple system atrophy (MSA) is a rare and fatal neurodegenerative disorder characterized by a variable combination of parkinsonism, cerebellar impairment, and autonomic dysfunction. The pathologic hallmark is the accumulation of aggregated α-synuclein in oligodendrocytes, forming glial cytoplasmic inclusions, which qualifies MSA as a synucleinopathy together with Parkinson's disease and dementia with Lewy bodies. The underlying pathogenesis is still not well understood. Some symptomatic treatments are available, whereas neuroprotection remains an urgent unmet treatment need. In this review, we critically appraise significant developments of the past decade with emphasis on pathogenesis, diagnosis, prognosis, and treatment development. We further discuss unsolved questions and highlight some perspectives. © 2019 International Parkinson and Movement Disorder Society.

Keywords: MSA; diagnosis; prognosis; treatment; α-synuclein.

PubMed Disclaimer

References

    1. Gilman S, Wenning GK, Low PA, et al. Second consensus statement on the diagnosis of multiple system atrophy. Neurology 2008;71(9):670-676.
    1. Lopez-Cuina M, Foubert-Samier A, Tison F, Meissner WG. Present and future of disease-modifying therapies in multiple system atrophy. Auton Neurosci 2018;211:31-38.
    1. Krismer F, Wenning GK. Multiple system atrophy: insights into a rare and debilitating movement disorder. Nat Rev Neurol 2017;13(4):232-243.
    1. Papp MI, Kahn JE, Lantos PL. Glial cytoplasmic inclusions in the CNS of patients with multiple system atrophy (striatonigral degeneration, olivopontocerebellar atrophy and Shy-Drager syndrome). J Neurol Sci 1989;94(1-3):79-100.
    1. Quinn N. Multiple system atrophy-the nature of the beast. J Neurol Neurosurg Psychiatry 1989(Suppl):78-89.

Publication types

MeSH terms

LinkOut - more resources